Project Grant R01CA292508
Award Date
4/14/25
Completion Date
3/31/30
Dollars Obligated
$694K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Cancer Institute (NCI) awarded a 3-year, $196,029 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Massachusetts Medical School (UMass Medical) to decipher the immune evasion mechanisms of mutant isocitrate dehydrogenase 1 (mIDH1) in cancer. The research aims to elucidate how mIDH1 creates an immunosuppressive tumor microenvironment through two distinct mechanisms: 1) suppression of innate immunity by silencing the cGAS sensor and viral...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $898,209 to the Dana-Farber Cancer Institute (DFCI) in Boston, MA to support research on the molecular dynamics of glioma formation and the DNA damage response of mutant IDH1 in lower-grade gliomas. The award aims to leverage a novel genetically engineered mouse model to address fundamental questions about mutant IDH1 biology, including determining the response to...
The National Cancer Institute (NCI) awarded a $655,306 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF) to leverage reactive metabolite generation as a therapeutic vulnerability in IDH-mutant gliomas, a deadly form of brain cancer. The project aims to: 1) determine if the combination of a brain-penetrant glyoxalase-1 inhibitor (BBG) and radiation is an effective treatment strategy in patient-derived...
The National Cancer Institute awarded a $701,408 Project Grant (CFDA 93.395 Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on enhancing the response to immune checkpoint blockade therapy in central nervous system metastases from breast cancer. The project aims to characterize mechanisms of resistance to immunotherapy in central nervous system metastases by profiling cancer and immune cells using...
The National Cancer Institute (NCI) awarded a $610,890 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic to conduct research on a novel combination therapy for intrahepatic cholangiocarcinoma, an aggressive liver cancer. The project aims to evaluate the clinical efficacy of combining external beam radiotherapy, autologous dendritic cell injections, and dual PD-L1/TIGIT checkpoint blockade. The study will assess progression-free survival as the primary endpoint and analyze...
The U.S. National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $620,820 Project Grant (CFDA 93.396 - Cancer Biology Research) to investigate CREB5-driven mechanisms of immune therapy resistance in cancer. The key objectives are to: 1) understand the molecular mechanisms governing CREB5 regulation and transcription; 2) identify CREB5-interacting proteins that drive collagen matrix deposition; and 3) elucidate how...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $793,324 to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme as a novel approach to treat hepatocellular carcinoma (HCC), including metabolic dysfunction-associated HCC. The key objectives are to: 1) identify CYP8B1 inhibitors through high-throughput screening, 2) validate hit compounds for potency,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support a study to investigate mechanisms by which a rare molecular subtype of prostate cancer with an isocitrate dehydrogenase 1 (IDH1) mutation fails to acquire resistance to therapy. The $421,042 award will fund research at The Johns Hopkins University to: 1) characterize the clinical, genomic, and transcriptomic features of IDH1-mutant prostate cancer; 2) develop a transgenic murine...
The National Cancer Institute (NCI) awarded a $689,934 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The grant will fund a large genome-wide association study (GWAS) covering over 13,000 patients receiving immune checkpoint inhibitor (ICI) cancer treatments. The study aims to characterize the genetic architecture underlying immune-related adverse events (IRAEs) associated with ICIs, and...
The federal Project Grant award of $662,516 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) is for research to investigate how fractionated radiation affects drug delivery in the tumor microenvironment for locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The project aims to 1) quantify how local radiation reshapes the tumor microenvironment to influence passive drug delivery using in vivo imaging, microscopy, and...